IFP Advisors’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-3
| Closed | -$9 | – | 5289 |
|
|
2026
Q2 | $9 | Sell |
3
-3
| -50% | -$8 | ﹤0.01% | 5095 |
|
|
2026
Q1 | $16 | Hold |
6
| – | – | ﹤0.01% | 4940 |
|
|
2025
Q4 | $22 | Buy |
6
+3
| +100% | +$10 | ﹤0.01% | 4798 |
|
|
2025
Q3 | $8 | Buy |
+3
| New | +$6 | ﹤0.01% | 4791 |
|
|
2023
Q3 | – | Sell |
-44
| Closed | -$61 | – | 3379 |
|
|
2023
Q2 | $61 | Hold |
44
| – | – | ﹤0.01% | 3380 |
|
|
2023
Q1 | $1.67K | Buy |
+44
| New | +$227 | ﹤0.01% | 2952 |
|
|
2020
Q1 | – | Sell |
-9
| Closed | -$475 | – | 2824 |
|
|
2019
Q4 | $1K | Hold |
9
| – | – | ﹤0.01% | 2652 |
|
|
2019
Q3 | $0 | Buy |
+9
| New | +$357 | ﹤0.01% | 3086 |
|
|
2019
Q1 | – | Sell |
-9
| Closed | – | – | 2658 |
|
|
2018
Q4 | $0 | Buy |
+9
| New | +$434 | ﹤0.01% | 3625 |
|
|
2017
Q2 | – | Sell |
-800
| Closed | -$28K | – | 4113 |
|
|
2017
Q1 | $28K | Buy |
800
+794
| +13,233% | +$18.2K | ﹤0.01% | 2280 |
|
|
2016
Q4 | $0 | Hold |
6
| – | – | ﹤0.01% | 4016 |
|
|
2016
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 3935 |
|
|
2016
Q2 | $0 | Buy |
+6
| New | +$99 | ﹤0.01% | 3889 |
|
Other funds holding ESPR
IFP Advisors's ESPR Position: Q3 2026 in Review
IFP Advisors sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 3 shares — an estimated $9 sold.
IFP Advisors first reported a position in ESPR in Q2 2016 and held it in 13 quarters. The position peaked at $28K in Q1 2017. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.
- IFP Advisors reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
- IFP Advisors sold 3 Esperion Therapeutics shares in Q3 2026, an estimated $9.
- IFP Advisors first reported a position in Esperion Therapeutics in Q2 2016 and held it in 13 quarters.
- IFP Advisors's Esperion Therapeutics position peaked at $28K in Q1 2017.
- 2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.
Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.